Clinical trial NCT02310919 - References

Infertility — Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

Citation(s)

•   Bianchi V, Dal Prato L, Maccolini A, Mazzone S, Borini A
  Inadvertent recombinant human follicle stimulating hormone bolus instead of human chorionic gonadotrophin leads to the retrieval of competent oocytes in IVF program. Fertil Steril. 2009 Nov;92(5):1747.e1-3. doi: 10.1016/j.fertnstert.2009.07.998. Epub 2009 Sep 3.
•   Chen X, Chen SL, He YX, Ye DS
  Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol. J Huazhong Univ Sci Technolog Med Sci. 2013 Feb;33(1):133-136. doi: 10.1007/s11596-013-1085-z. Epub 2013 Feb 8.
•   Egbase PE, Sharhan MA, Masangcay M, Egbase E
  Follicle stimulating hormone (FSH) administer with trigger dose human chorionic gonadotropin (hCG) completely prevents ovarian hyperstimulation (OHSS): Randomised controlled study. [Abstract] Fertil Steril 2011; 96(3): S20.
•   Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E
  Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989 Jun;44(6):430-40. Review.
•   Hoff JD, Quigley ME, Yen SS
  Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983 Oct;57(4):792-6.
•   Kashyap S, Parker K, Cedars MI, Rosenwaks Z
  Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med. 2010 Nov;28(6):475-85. doi: 10.1055/s-0030-1265674. Epub 2010 Nov 16. Review.
•   Klemetti R, Sevón T, Gissler M, Hemminki E
  Complications of IVF and ovulation induction. Hum Reprod. 2005 Dec;20(12):3293-300. Epub 2005 Aug 26.
•   Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P
  Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil Steril. 2007 Nov;88(5):1382-8. Epub 2007 Apr 18.
•   Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP
  Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011 Apr;95(5):1655-60. doi: 10.1016/j.fertnstert.2011.01.019.
•   McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM
  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994 Jul 23;344(8917):235-6.
•   Navot D, Bergh PA, Laufer N
  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992 Aug;58(2):249-61. Review. Erratum in: Fertil Steril 1993 Jun;59(6):1334.
•   Schmidt DW, Maier DB, Nulsen JC, Benadiva CA
  Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril. 2004 Oct;82(4):841-6.
•   Tsoumpou I, Muglu J, Gelbaya TA, Nardo LG
  Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online. 2009 Jul;19(1):52-8. Review.
•   Wikland M, Borg J, Forsberg AS, Jakobsson AH, Svalander P, Waldenström U
  Human chorionic gonadotrophin self-administered by the subcutaneous route to induce oocyte maturation in an in-vitro fertilization and embryo transfer programme. Hum Reprod. 1995 Jul;10(7):1667-70.
•   Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL
  A bolus of recombinant human follicle stimulating hormone at midcycle induces periovulatory events following multiple follicular development in macaques. Hum Reprod. 1998 Mar;13(3):554-60.

Concomitant Administration of FSH With a Low Dose of hCG (1,500 IU) Has Equivalent Oocyte Developmental Competence While Decreasing the Exposure to hCG in IVF Cycles: A Double Blind Randomized Control Trial

Details for clinical trial NCT02310919